Published by Josh White on 4th April 2023
(Sharecast News) - Destiny Pharma said in an update on Tuesday that its novel medicine for preventing life-threatening infections, 'NTCD-M3', had been shown to colonise the gut successfully in a C difficile infection (CDI) model study after the administration of fidaxomicin.
URL: http://www.digitallook.com/dl/news/story/33414862/...